# Evolus, Inc.

Type: Company (EOLS)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/evolus-inc
Canonical HTML page: https://gethealthbrief.com/entity/evolus-inc

## Timeline

- **2026-03-04**: Earnings Release — Company reports Q4 beat and issues bullish 2026 revenue guidance.
- **2026**: Evolysse Launch — Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
- **2025-12-31**: Q4 Fiscal Close — Evolus concludes its strongest fiscal year to date with record Jeuveau sales.

## Recent coverage (1 stories)

### Evolus Surges on Q4 Beat as Jeuveau Gains Ground in Medical Aesthetics
2026-03-05 22:42:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
Full story: https://gethealthbrief.com/story/evolus-q4-2025-earnings-analysis-jeuveau-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.